HIIT Vereus Moderate Continuous Training in ACHD

Adults with congenital heart disease (ACHD) have reduced exercise capacity which is an independent predictor of adverse outcome including hospitalization and mortality in this patient population. When aerobic exercise capacity is measured by cardiopulmonary exercise testing (CPET), peak oxygen consumption (peak VO2) averages 22ml/kg/min in ACHD, less than half of age matched controls, and similar to patients with heart failure. Factors contributing to low exercise capacity include central factors related to abnormal cardiac anatomy, ventricular systolic and diastolic dysfunction, valvular abnormalities, pulmonary hypertension, chronotropic incompetence and impaired pulmonary function as well as peripheral factors such as skeletal muscle conditioning. Clinicians may further contribute to reluctance around exercise by failing to encourage physical activity or giving inappropriate exercise restrictions to ACHD. The aim of our study was to explore the efficacy of HIIT compared to MCT on aerobic exercise capacity as measured by peak VO2 in ACHD patients. Secondary aims were to determine the effect of exercise on various physiologic variables, to assess the safety of HIIT in ACHD, to evaluate the effect of exercise training on cardiac structure and function as assessed by cardiac MRI and to measure the impact of exercise training on quality of life (QoL). This was a single center randomized controlled trial designed in accordance with CONSORT guidelines. Participants were randomized with a 1:1:1 ratio into three groups: HIIT, MCT or control group. Randomization occurred by clusters defined by week of attendance in the clinic. Permuted blocks of 3, 6, and 9 were used to ensure a similar number of weeks randomized to the three groups, with randomization sequence generated by one author (AM). Participants were enrolled by a study coordinator who assigned participants to one of the three groups. Participants underwent testing at baseline and after 12 weeks of the intervention.